A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis With Inadequate Response to or for Whom Cyclosporine A is Not Medically Advisable

The primary objective of this study is to investigate the efficacy of nemolizumab administered in combination with topical background therapy (topical corticosteroids [TCS] with or without topical calcineurin inhibitors [TCI]) in adult participants with moderate-to-severe atopic dermatitis (AD) who are not adequately controlled with or are not advised to use oral cyclosporine A (CsA) for medical reasons. The secondary objective is to investigate the safety of nemolizumab in adult participants with moderate-to-severe AD who are not adequately controlled with or are not advised to use oral CsA for medical reasons.
The study will be carried out in up to 70 different locations across Europe.

Start Date01 Jan 2023

Sponsor / Collaborator

Galderma Holding SA

NCT05405985

/ CompletedPhase 1

A Randomized, Single-Dose, Open-Label, Parallel-Group Study in Healthy Volunteers to Assess the Relative Bioavailability of a Subcutaneous Dose of Nemolizumab When Administered With Auto-Injector Compared to Dual-Chamber Syringe

This study was to compare the rate and extent of absorption of a single dose of nemolizumab administered with auto-injectors [AI] (test) versus dual-chamber syringes [DCS] (reference) under controlled conditions in healthy adult subjects.

Start Date11 Aug 2022

Sponsor / Collaborator

Galderma Holding SA

NCT05445661

/ Unknown statusNot ApplicableIIT

A Single Center, Double-Blinded, Split-Body, Randomized Clinical Trial of Injectable Poly-L-Lactic Acid for the Treatment of Upper Inner Arm Skin Crepiness/Laxity

To assess the safety, efficacy, and patient satisfaction associated with the treatment of upper inner arm crepiness/laxity with injectable poly-L-lactic acid (PLLA, Sculptra® Aesthetic; Galderma Laboratories; Fort Worth, TX).

Start Date20 Jul 2022

Sponsor / Collaborator

Galderma Holding SA

100 Clinical Results associated with Galderma Holding SA

0 Patents (Medical) associated with Galderma Holding SA

Literatures (Medical) associated with Galderma Holding SA

01 Dec 2025·Journal of Cosmetic Dermatology

A Prospective, Randomized, Double‐Blind, Split‐Face Trial Evaluating the Effects of Pre‐Conditioning With a TriHex Technology Serum Nectar 2.0 Versus a Vehicle in Subjects Undergoing Elective Facelift Surgery

Article

Author: Sadrian, Reza ; Moradi, Amir ; Shafiq, Faiza ; Robison, Tiffany ; Riedler, Kiersten ; Widgerow, Alan D.

ABSTRACT:

Background:

Preconditioning of skin prior to procedures with the Alastin TriHex Technology has been demonstrated to enhance procedure outcomes. Alastin Regenerating Skin Nectar with TriHex Technology Serum (Alastin Skincare Inc. Carlsbad, CA) has undergone reformulation to include an added Octapeptide‐45 for improving post‐surgical outcomes and healing through pre‐conditioning. A 5‐week clinical trial was conducted to demonstrate efficacy and safety for post‐surgical skin wound healing (following pre‐conditioning), and overall skin health. In particular, molecular and cellular changes were documented, histologically comparing the treated side against the vehicle on the opposite side.

Methods:

A randomized, double‐blinded, split‐face, comparative study was conducted in 5 patients to evaluate the effects of pre‐conditioning with a TriHex Technology Serum 2.0 (Nectar 2.0) compared to vehicle in subjects undergoing elective facelift surgery. Patient questionnaires and investigator assessments were undertaken, and baseline biopsies were taken from both sides 4 weeks prior to surgery. Following the facelift surgery, collected skin samples from each side of the face were analyzed for histological changes comparing pre (screening) and post (4 weeks) of pre‐conditioning use of study topicals by an independent dermatopathologist using multiple staining techniques.

Results:

Investigator assessment with facial aesthetic clinical grading scale demonstrated greater improvements for the Nectar 2.0 treatment side compared to vehicle at Day 7 from screening for all assessed parameters: skin dullness, fine lines, tactile roughness, global photodamage. Investigator healing assessments demonstrated improved Healing on the Nectar 2.0 treatment side compared to vehicle, related to erythema, edema, and crusting parameters. Histological differences between the two sides were significant with major changes in extracellular matrix composition involving collagen, elastin and hyaluronic acid production and reversal of solar elastosis, all Evident only on the Nectar 2.0 treated side.

Conclusion:

A randomized, double‐blinded, split‐face, comparative study with Alastin Regenerating Skin Nectar with TriHex + Technology Serum 2.0 revealed that pre‐conditioning resulted in significant improvement in healing, global skin health and histological results with marked remodeling of the ECM being observed in all patients. A short period of pre‐conditioning can have substantial effects on skin health and procedure outcomes.

01 Apr 2025·Journal of Cosmetic Dermatology

A Multi‐Center Clinical Trial to Evaluate the Efficacy of the Next Generation TriHex Technology Antiaging Regimen

Article

Author: Widgerow, Alan D. ; Robison, Tiffany ; Boyd, Charles ; Gold, Michael ; Shafiq, Faiza ; Mraz, Deanne

ABSTRACT:

Background:

Alastin Restorative Skin Complex Serum with TriHex Technology (Alastin Skincare Inc., Carlsbad, CA) has undergone reformulation to add Octapeptide‐45 and magnolol for improving facial skin hydration, elasticity, plumping, and overall skin quality. Detailed science on TriHex Technology 2.0 and magnolol has been recently published. This open‐label study was conducted to validate the science and demonstrate product efficacy and tolerability in individuals with moderate to severe facial skin aging.

Methods:

A multi‐center clinical study was conducted from February to August 2024. A total of 44 eligible participants (43 female, 1 male), ages 35–69 years, and Fitzpatrick skin Types I–VI were enrolled in and completed the study following 12 weeks of Alastin Restorative Skin Complex Serum 2.0 with TriHex Technology (RSC 2.0) use twice daily, along with an Alastin Skincare Inc. supportive regimen (cleanser, moisturizer, sunscreen used as needed). A 1‐week run‐in phase using the supportive regimen only was conducted, and eligibility was reassessed at baseline. Follow‐up visits were performed at Weeks 4, 8, and 12, where facial skin quality parameters were evaluated clinically and subject assessments and satisfaction questionnaires, biopsy collection, photography, and hydration and elasticity measurements were completed. Participants also maintained a study diary over the 12‐week treatment period.

Results:

Significant improvements for all clinically evaluated facial skin parameters were achieved at Week 12. Histology revealed increased stimulation of new adipocytes, epidermal keratinocyte HA (CD44), and new dermal collagen and elastin fibers post treatment.

Conclusion:

Alastin Restorative Skin Complex Serum 2.0 with TriHex Technology has been demonstrated to be safe and effective for improving overall facial skin quality, achieving notable improvements in volume, plumping, hydration, and extracellular matrix (ECM) collagen and elastin stimulation.

01 Jul 2023·Journal of cutaneous medicine and surgery

Management of Acne Vulgaris With Trifarotene

Review

Author: Dreno, Brigitte ; Tan, Jerry ; Chavda, Rajeev ; Baldwin, Hilary

Topical retinoids have an essential role in treatment of acne. Trifarotene, a topical retinoid selective for retinoic acid receptor (RAR) γ, is the most recent retinoid approved for treatment of acne. RAR-γ is the most common isoform of RARs in skin, and the strong selectivity of trifarotene for RAR-γ translates to efficacy in low concentration. Trifarotene, like other topical retinoids, acts by increasing keratinocyte differentiation and decreasing proliferation, which reduces hyperkeratinization. Retinoids have also been shown to inhibit inflammatory pathways via effects on leukocyte migration, toll-like receptors, and Activator Protein (AP)−1. Large-scale randomized, controlled clinical trials have demonstrated trifarotene to be safe, well tolerated, and efficacious in reducing both comedones and papules/pustules of acne. However, unlike all other retinoids, trifarotene is the first topical retinoid with rigorous clinical data on safety and efficacy in truncal acne. Data supporting use of trifarotene to manage acne are reviewed in this publication.

173

News (Medical) associated with Galderma Holding SA

22 Jan 2026

·endpoints.news

A trio of biotechs targets $500M+ offerings

Plus, news about Ipsen, Galderma, PAQ Therapeutics and Resolve M Therapeutics: 💰 Public offering roundup: 📜 Tribunal sides with Ipsen in dispute with Galderma: The International Chamber of Commerce has dismissed Galderma’s claim in the arbitration proceedings, which relates to Ipsen’s decision to end an R&D deal between the companies that dates back to 2014. The agreement was focused on neuromodulators. Galderma said the decision has no impact on its commercial neuromodulator franchise. — Ayisha Sharma 💵 PAQ expands Series B: The Burlington, MA-based startup boosted its Series B to $77 million. It was initially $39 million in May 2025. The biotech also dosed the first patient in a trial of its pan-KRAS degrader called PT0511. — Kyle LaHucik 🤝 Resolve M Therapeutics leaves stealth: The Cambridge, MA-based biotech was created through a “strategic collaboration” between Johnson & Johnson Innovation and General Inception. The company is focused on treating chronic inflammatory and autoimmune disorders. — Ayisha Sharma

Patent Infringement

21 Jan 2026

·www.galderma.com

Galderma provides update on arbitration case regarding neuromodulator research and development partnership

Zug, Switzerland – January 21, 2026 – Galderma (SIX:GALD), the pure-play dermatology category leader, today announced that an International Chamber of Commerce arbitral tribunal issued an award confirming the termination of a 2014 neuromodulator research & development partnership with Ipsen. The partnership was limited to the rights and obligations relating to the companies’ early-stage neuromodulator pipeline for aesthetic indications. Galderma welcomes the clarity provided by the arbitral tribunal. This decision has no impact on the commercialization of Galderma’s neuromodulator portfolio. Galderma will continue to commercialize and supply Dysport®/Azzalure®, Alluzience®, and RelfydessTM in all territories where it has regulatory approval and in accordance with our existing agreements with our partner Ipsen. Galderma remains focused on its ambition to become the world’s undisputed dermatology powerhouse across the full spectrum of a fast-growing market, spanning Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Galderma’s business model is flexible – from in-house development to external partnerships. In Injectable Aesthetics specifically, Galderma is on a strong trajectory to become the global leader, not just in sales and market share, but also in innovation. The company is well positioned to lead across the full value chain, with in-house capabilities spanning the discovery, research, development, manufacturing, and marketing of best-in-class products globally. We have proven our capabilities with Restylane® – the broadest HA filler portfolio in the industry; Sculptra® – the first proven regenerative biostimulator; and more recently with RelfydessTM – the first and only ready-to-use liquid neuromodulator created with our proprietary PEARLTM Technology. Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com. For further information: Christian Marcoux, M.Sc. Chief Communications Officer christian.marcoux@galderma.com +41 76 315 26 50 Emil Ivanov Head of Strategy, Investor Relations, and ESG emil.ivanov@galderma.com +41 21 642 78 12 Richard Harbinson Corporate Communications Director richard.harbinson@galderma.com +41 76 210 60 62 Jessica Cohen Investor Relations and Strategy Director jessica.cohen@galderma.com +41 21 642 76 43 Follow us on Social Media for current news and patients stories

21 Jan 2026

·www.galderma.com

IMCAS 2026: Galderma’s scientific presentations

Galderma will present data from across its broad Injectable Aesthetics portfolio at the International Master Course on Aging Science (IMCAS) 2026 World Congress in Paris, France, from January 29-31, 2026. First author Poster title Presentation type A. HaddadInternational consensus: Sculptra®/Restylane® Skinboosters™ for non-facial rejuvenation e-PosterA. NikolisPreferences and experiences across biostimulatory poly-L-lactic acid’s reconstitution processes and injection criteria (PREP study) e-PosterSG. FabiRegenerative aesthetic effects of poly L-lactic acid treatment e-PosterSG. FabiThe potential role of biostimulators/dermal fillers to address menopause-related skin conditions e-PosterA. NikolisA new NASHA-HD, high G’ hyaluronic acid (HA) injectable evaluated for chin treatment in combination with lower face and midface HA filler treatment e-PosterJ. RiversEffectiveness and safety of Restylane® Lyft™ Lidocaine for jawline definition: A 12-month randomized controlled study e-PosterA. MoradiEffectiveness and safety of a hyaluronic acid skin quality injectable for the correction of wrinkles in the décolletage area e-PosterM. NestorSafety and effectiveness of an OBT™ hyaluronic acid filler for temple hollowing treatment: a randomized, controlled, clinical investigation e-PosterB. AscherConsensus Recommendations on the Aesthetic Use of RelabotulinumtoxinA to Treat Upper Face Wrinkles e-PosterA. MoradiObjective image analysis of wrinkle morphology and dynamic skin strain in GLs and LCLs treated with relaBoNT-A in the RELAX and EXPRESSION trialse-Poster Galderma will showcase its superior educational capabilities through two symposia and a live anatomy workshop at the congress. SpeakersEvent type & title Details Dr. Hugues Cartier Dr. Sebastien Garson Dr. Dalvi Humzah Dr. Kai Oliver Kaye Dr. Marina Landau Live anatomy cadaver workshopThursday, January 29 10:00 AM – 12:30 PM CET Grand Amphitheatre, Level 1 Dr. Andreas Nikolis Dr. Sabrina Fabi Dr. Alessandra Haddad Dr. Michael Somenek Dr. Steve Dayan Exploring Breakthroughs in Injectable Regeneration for the Face, Body, and Skin Health – Symposium Thursday, January 29 1:30 PM – 2:30 PM CET Room 251, Level 2 Dr. Andreas Nikolis Dr. Stephanie Lam Dr. Sabrina Fabi Dr. Alessandra Haddad Dr. Steven Liew Dr. Steve Dayan Menopause in the Mirror: Challenges, Science and Aesthetic Solutions – SymposiumFriday, January 30 10:30 AM – 12:30 PM CET Grand Amphitheatre, Level 1 Dr. Hugues Cartier Dr. Sebastien Garson Dr. Dalvi Humzah Dr. Kai Oliver Kaye Dr. Marina Landau Thursday, January 29 10:00 AM – 12:30 PM CET Grand Amphitheatre, Level 1 Dr. Andreas Nikolis Dr. Sabrina Fabi Dr. Alessandra Haddad Dr. Michael Somenek Dr. Steve Dayan Thursday, January 29 1:30 PM – 2:30 PM CET Room 251, Level 2 Dr. Andreas Nikolis Dr. Stephanie Lam Dr. Sabrina Fabi Dr. Alessandra Haddad Dr. Steven Liew Dr. Steve Dayan Friday, January 30 10:30 AM – 12:30 PM CET Grand Amphitheatre, Level 1 All authors are paid consultants of Galderma. Follow us on Social Media for current news and patients stories

100 Deals associated with Galderma Holding SA

100 Translational Medicine associated with Galderma Holding SA

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 02 Feb 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

Approved

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Nemolizumab ( IL-31RA )	Severe Atopic Dermatitis More	Approved
Trifarotene ( RARγ )	Acne Vulgaris More	Approved
Methyl Aminolevulinate Hydrochloride	Actinic Keratosis More	Approved
Adapalene ( RARs )	Acne Vulgaris More	Approved
Amorolfine Hydrochloride ( Ergosterol x SQLE )	Skin Diseases, Infectious More	Approved

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis